Can GLP-1 Cause Anxiety?

Can GLP-1 cause anxiety? Some users do report feeling more anxious after starting GLP-1 receptor agonists, and certain observational research has linked these compounds to higher anxiety-related outcomes in specific populations. After a comprehensive review of clinical trial data across GLP-1 compounds, the FDA found no increased risk for anxiety, depression, or related psychiatric outcomes. That finding, published in January 2026, covers the specific concern most often raised in consumer discussions about this topic.

GLP-1 receptors exist in brain areas tied to appetite signaling and emotional processing, connecting digestion directly to the nervous system. Fast body changes and shifts in daily routine during GLP-1 use may also shape how people feel emotionally.

Anxious feelings may reflect several overlapping factors: the compound itself, digestive discomfort, lower food intake, disrupted sleep, or the psychological weight of rapid physical change. This article examines what the evidence shows and where it genuinely conflicts.

Key Article Findings

Current evidence on GLP-1 and anxiety is mixed; some studies find higher anxiety-related outcomes, while others report neutral or lower rates.
GLP-1 receptors appear in brain regions involved in emotional processing, which is why researchers have been studying mood-related effects.
Digestive side effects, reduced food intake, and sleep disruption may contribute to anxious feelings indirectly.
Some users report improved emotional wellbeing over time, though this does not reflect a confirmed anxiety benefit.

What Studies Say About GLP-1 and Anxious Feelings

The current body of research does not deliver a clean answer. One large observational study found significantly higher rates of anxiety-related outcomes among GLP-1 receptor agonist users. Other analyses, including a large database study covering millions of patient records, found that most GLP-1 agents were associated with lower anxiety rates in certain populations.

In January 2026, following a comprehensive meta-analysis of 91 placebo-controlled trials covering over 107,000 participants, the FDA concluded that GLP-1 compounds did not show an increased risk for anxiety, depression, or related psychiatric outcomes compared to placebo.

Why findings look so different comes down to who was studied, what health profiles they had at the start, how long they were followed, and how anxiety was defined. The table below captures the core tension in current evidence.

Source Type	Population Studied	Main Finding	What Limits the Conclusion
Retrospective cohort	Adults managing weight, no prior psychiatric history	Higher anxiety-related outcomes in GLP-1 group	Observational design; cannot confirm causation
Large database analysis	Adults with and without metabolic conditions	Lower anxiety rates in most GLP-1 groups	Populations and comparator groups differ significantly
Regulatory review	General GLP-1 user population	No confirmed causal link identified	Based on adverse event reports, not clinical trials

What One Large Study Found

A 2024 retrospective cohort study published in Scientific Reports analyzed records from over 162,000 matched adults prescribed GLP-1 receptor agonists for weight-related purposes.

Those using GLP-1 receptor agonists had notably higher rates of anxiety-related outcomes compared to matched controls. This was an association found in real-world data, not a controlled trial, and the study design does not allow for confirmation that the compound directly caused the outcomes observed.

Why Other Evidence Sounds Different

Studies on GLP-1 and anxiety reach different conclusions for identifiable reasons. Population profiles, follow-up length, comparator groups, and how anxiety is defined all shape what each analysis finds.

A large database study drawing on records from over 233 million patients found that most GLP-1 agents were associated with lower anxiety rates in certain populations. Neither direction should be read as settled. Readers interested in related topics may find the article on ashwagandha and stress research a useful starting point for broader reading.

GLP-1 and Anxiety: Why the Connection May Feel Different

Worried woman sitting by a window with her hands covering her face

Not every anxious feeling during GLP-1 use reflects a direct neurological effect. Appetite changes, digestive adjustments, and lower calorie intake can each affect emotional tone on their own. GLP-1 and anxiety may feel closely connected for reasons that have nothing to do with the compound acting on mood pathways directly.

Separating the compound’s possible role from the many other changes happening at the same time is part of what makes this topic genuinely difficult to study. That complexity is worth keeping in mind when interpreting both personal experience and research headlines.

The Gut-Brain Axis and Appetite Signaling

GLP-1 receptors appear not only in the digestive tract but in brain regions linked to appetite and how the body responds to stress. For more background, the article on how GLP-1 works provides a useful starting point. This overlap between gut and brain signaling is why researchers have been examining mood-related effects closely. It does not mean these compounds produce predictable or uniform changes in emotional tone.

When Side Effects Can Influence Mood Indirectly

Persistent nausea, digestive discomfort, and reduced appetite can take a real emotional toll over time. A mixed-methods analysis of user reports across Reddit, YouTube, and TikTok found that sleep disruption, GI symptoms, and anxious feelings were among the most commonly described experiences during GLP-1 use. Several indirect contributors may leave some people feeling more on edge during early or dose-escalation phases:

Persistent nausea affecting sleep quality and daily comfort
Lower calorie intake reducing energy levels and mental sharpness
Disrupted sleep from GI symptoms or appetite changes
Reduced enjoyment of meals and food-related social situations
Fatigue as the body adjusts to new appetite patterns

These effects often ease over time. Understanding more about why nausea occurs with GLP-1 receptor agonists can help set realistic expectations for what the adjustment period typically looks like.

The Social Side of Rapid Body Change

When body composition shifts quickly, some people describe feeling more visible, self-conscious, or unsettled in social situations. Clothes fit differently, others respond differently, and a person’s sense of self may take time to align with physical changes. This is not a universal experience and does not reflect a pharmacological effect. Still, it may contribute to heightened emotional sensitivity that some users attribute to the compound itself.

What Some Users Report About Mood and GLP-1

Man sitting on a park bench holding a cup and looking relaxed

Does GLP-1 help with anxiety? Some users describe feeling calmer as physical wellbeing improves and daily routines stabilize, but that is not the same as a confirmed effect on anxiety. A 2025 systematic review and meta-analysis found no increased risk of psychiatric adverse events with GLP-1 receptor agonists in placebo-controlled trials and reported improvements in mental-health-related quality of life, emotional eating, and eating restraint, though this does not establish an anxiety benefit.

Personal reports of feeling better are not the same as a confirmed anxiety benefit. Many changes unfold simultaneously during GLP-1 use, and isolating the compound’s contribution to emotional wellbeing requires more controlled data than currently exists.

Why Some Users Report Feeling Better

Reduced food noise, more consistent hunger patterns, and a growing sense of physical progress may each contribute to improved emotional tone. A nationwide, population-based cohort study found a significantly lower rate of anxiety-related diagnoses in people with specific metabolic health profiles using GLP-1 compounds, compared to matched controls. This observational finding aligns with what some users describe, though it does not establish a causal benefit.

Why “Feeling Better” Is Not the Same as a Proven Mood Benefit

Improved physical comfort, more stable habits, and growing confidence are all plausible drivers of positive mood shifts during GLP-1 use. None of these point specifically to an anxiety-support mechanism in the compound. Current evidence does not support recommending GLP-1 receptor agonists as anxiety support tools, and the data, while suggestive in places, is too inconsistent across populations to support that conclusion.

What to Watch For if Anxiety Feels Worse After Starting a GLP-1

If anxious feelings increase after starting a GLP-1 compound, examining what else may have changed is a practical first step. Timing, sleep quality, food intake, and digestive comfort are all worth noting. The goal is not to generate worry but to support calm, informed self-observation over the first several weeks.

What to Notice	Why It May Matter	What to Track
When anxious feelings began	May correspond to dose escalation or early adjustment	Timing relative to dose changes
Sleep quality	Poor sleep amplifies anxious feelings independently	Hours slept and sense of restfulness each morning
Nausea or GI discomfort	Ongoing physical discomfort affects emotional steadiness	Frequency, severity, and time of day
Food and water intake	Low intake can reduce energy and emotional resilience	Approximate daily amounts
Mood patterns around meals	May reflect changes in appetite signaling	How mood tracks relative to mealtimes

Changes Worth Tracking

The most informative observations center on timing and context. Note whether anxious feelings appear near dose changes, during periods of low food intake, or alongside active digestive discomfort. Pay attention to whether these feelings are new or mirror emotional patterns that existed before starting. Tracking these alongside sleep quality and hydration over two to four weeks can help distinguish a typical adjustment phase from something more persistent.

When Extra Support Matters

Mood changes that escalate quickly or significantly disrupt daily functioning are worth discussing promptly with a qualified healthcare professional. This is not a common outcome, but it deserves direct acknowledgment. Those interested in how food choices relate to day-to-day wellbeing may find the article on nutrition and the nervous system useful additional reading.

Conclusion

The question of whether GLP-1 can cause anxiety does not have a clean answer. Some observational research has found higher anxiety-related outcomes in specific populations, while other analyses suggest neutral or lower rates. Individual response, study design, and the many simultaneous changes during GLP-1 use all shape what the evidence shows. Paying close attention to sleep, digestion, food intake, and emotional patterns remains the most practical and grounded approach for anyone navigating this period.

Does GLP-1 Cause Anxiety?

Not definitively. Some observational studies have found higher anxiety-related outcomes in GLP-1 users, while others have not. Regulatory reviews have not confirmed a direct cause-and-effect relationship, and individual responses vary significantly.

Can GLP-1 Make Anxiety Worse in Some People?

Yes, some users report increased anxious feelings, particularly during early use or dose escalation. Digestive discomfort, disrupted sleep, and reduced food intake may also contribute to those feelings indirectly.

Is the Link Between GLP-1 and Anxiety Proven?

No. Current research shows associations in some studies but does not confirm causation. Regulatory bodies have not validated a direct link, and findings vary widely across different populations and study designs.

Why Do Studies on GLP-1 and Anxiety Seem to Disagree?

Studies differ in population, follow-up period, comparator groups, and how anxiety is measured. A study of people managing weight may yield different results than one focused on people managing blood sugar levels, even using similar compounds.

U.S. Food and Drug Administration. (2026). FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp

Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 14, Article 24433.

https://www.nature.com/articles/s41598-024-75965-2

Miller, A., Joyce, B., Bartelt, K., & Deckert, J. (2024). Most GLP-1 medications correlated with a lower likelihood of anxiety and depression diagnoses. Epic Research.

https://www.epicresearch.org/articles/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-depression-diagnoses

Anderberg, R. H., Richard, J. E., Hansson, C., Nissbrandt, H., Bergquist, F., & Skibicka, K. P. (2016). GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology, 65, 54–66.

https://pubmed.ncbi.nlm.nih.gov/26724568/

Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Schifano, F., & Martinotti, G. (2023). GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain Sciences, 13(11), Article 1503.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10669484/

Pierret, A. C. S., Mizuno, Y., Saunders, P., Djemai, B., Chanut, M., & McIntyre, R. S. (2025). Glucagon-like peptide-1 receptor agonists and mental health: A systematic review and meta-analysis. JAMA Psychiatry, 82(6), 643–653.

https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2833558

Tsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., & Wu, S.-I. (2022). Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study. Frontiers in Pharmacology, 13, Article 765446.

https://pubmed.ncbi.nlm.nih.gov/35281896/

Advertisement. This site offers health, wellness, fitness and nutritional information and is designed for educational purposes only. You should not rely on this information as a substitute for, nor does it replace, professional medical advice, diagnosis, or treatment. If you have any concerns or questions about your health, you should always consult with a physician or other health-care professional. Do not disregard, avoid or delay obtaining medical or health related advice from your health-care professional because of something you may have read on this site. The use of any information provided on this site is solely at your own risk.